The main point of investing for the long term is to make money. But more than that, you probably want to see it ...

Abbott Laboratories (NYSE:ABT) is preparing to release its quarterly earnings on Thursday, 2025-07-17. Here's a brief overview of what investors should keep in mind before the announcement. Analysts ...

If you have been wondering whether Abbott Laboratories is still a buy at around $125 a share, you are not alone. This is exactly the kind of stock where valuation really matters. Despite slipping ...

Discover why Abbott Laboratories (ABT) earns a buy rating with strong fundamentals, dividend growth, and growth prospects.

I think I have uncovered the real reason why Abbott Laboratories (NYSE:ABT) decided to spin off its pharmaceutical division into AbbVie Inc (NYSE:ABBV). The new company — now focused solely on medical ...

If you wonder whether Abbott Laboratories (NYSE: ABT) is a good buy in Q2 2025, the answer is yes. The company’s management, portfolio, cash flow, capital return, and pipeline are why. The stock price ...

Parnassus Investments, an investment management firm, released its “Parnassus Value Equity Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund focuses on ...

Litigation that could cost the company billions has it on the offensive — and asking for the government to intervene.

Detailed price information for Abbott Laboratories (ABT-N) from The Globe and Mail including charting and trades.

The FDA approved Abbott's Volt PFA System for atrial fibrillation, supported by VOLT-AF trial data showing strong safety and ...

Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. Abbott Laboratories is moving to replace more than a ...